Change template to: full
D. Minimal residual disease
Detection of minimal residual disease (MRD) by flow cytometry in children with acute lymphoblastic leukemia (ALL)
Margarita G. Bozhieva, Ludmila Y. Grivtsova, Alexander V. Popa, Irina N. Serebryakova, Irina E. Gavrilova, Boris V. Kurdyukov, Rono S. Ravshanova, Georgiy L. Mentkevich, Nikolay N. Tupitsyn
Comparison of MRD data assessed by flow cytometry and RT-PCR of fusion gene transcripts in infants with MLL-rearranged ALL
Alexander M. Popov1,2,3, Grigory A. Tsaur1,2, Anna S. Ivanova1,2, Yulia A. Yakovleva1,2, Tatiana Y. Verzhbitskaya1,2, Tatiana O. Riger1, Egor V. Shorikov1,2, Leonid I. Savelyev1,2,3, Larisa G. Fechina1,2
Slow fusion gene transcript clearance predicts poor outcome in infants with MLL-rearranged acute lymphoblastic leukemia
Grigory A. Tsaur1,2, Tatyana V. Nasedkina3, Alexander M. Popov1,2,4, Anna S. Ivanova1,2, Yulia A. Yakovleva1,2, Tatyana O. Riger1,2, Egor V. Shorikov1,2, Leonid I. Saveliev1,2,4, Larisa G. Fechina1,2
Algorithm for monitoring minimal residual disease on the basis of patient-associated immunophenotypes
Yekaterina E. Zueva, Margarita V. Gorchakova, Ekaterina B. Rusanova, Konstantin U. Slobodnyuk